Healthcare Business Recap: NuSkin ACCUSED Of Lying About Products, Myriad Genetics’ Mixed DECISION
Nu Skin Enterprises Inc. (NYSE:NUS) is accused by Citron Research of instructing its sales representatives to prevaricate if questioned regarding the actual scientific basis of its product claims. Chief Financial Officer Ritch Wood defended his firm’s China model in an interview Wednesday, avowing confidence that it’s “kosher,” thus no changes are necessary.
Don’t Miss: Intuit Fourth Quarter Earnings Sneak Peek.
Gilead Sciences, Inc. (NASDAQ:GILD) Phase 3 Neutrino evaluation in patients suffering from Hepatitis C was fully enrolled in July following only one month of recruitment, which implies tremendous potential demand for the company’s Hepatitis C treatment GS-7977, says Citigroup, as it maintains its Buy along with a price target of $65.
Drug developer Myriad Genetics, Inc. (NASDAQ:MYGN) on Thursday received a mixed court decision which reversed a lower court ruling that had said that the firm’s isolated” DNA molecules were not eligible for patents. At the same time, the court also upheld the lower court’s decision that Myriad’s methods for comparing or analyzing DNA are not eligible for patents. However, the firm says it’s still a win, as the gene patent claims were paramount in importance.
Shares of the oncology treatment specialist Geron Corporation (NASDAQ:GERN) jump, perhaps because of a positive SA blog that suggests a buy for investors looking for some speculation in their portfolios. The article said that Geron’s drugs “have the potential to change the way cancer is treated”, pointing to six potential catalysts for Geron’s stock over the next year.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.